Fujimycin
Categorie
Fujimycin Les marques, Fujimycin Analogs
Fujimycin Les marques melange
Fujimycin Formule chimique
C25H37NO4
Fujimycin RX lien
http://www.rxlist.com/cgi/generic/salmeterol.htm
Fujimycin FDA fiche
Fujimycin msds (fiche de securite des materiaux)
Fujimycin Synthese de reference
SI Skidmore et al., US. 4.992.474 (1991).
Fujimycin Poids moleculaire
415.566 g/mol
Fujimycin Point de fusion
75.5-76.5 oC
Fujimycin H2O Solubilite
Modérément soluble
Fujimycin Etat
Solid
Fujimycin LogP
5.022
Fujimycin Formes pharmaceutiques
Inhalateurs-doseurs (aérosol); Poudre
Fujimycin Indication
Pour le traitement de l'asthme et maladie pulmonaire obstructive chronique (MPOC).
Fujimycin Pharmacologie
Le salmétérol est un long bêta2-adrénergiques (LABA), habituellement prescrit pour que l'asthme persistant sévère suite à un traitement précédent avec un agoniste bêta à action brève comme le salbutamol et la est prescrit simultanément avec un corticostéroïde, comme béclométasone. La principale différence notable de salmétérol au salbutamol est que la durée d'action dure environ 12 heures en comparaison avec 4-6 heures de salbutamol. Lorsqu'il est utilisé régulièrement chaque jour comme presecribed, salmétérol en inhalation réduit le nombre et la gravité des crises d'asthme. Toutefois, il n'est pas pour une utilisation pour soulager une crise d'asthme qui a déjà commencé. Salmétérol en inhalation fonctionne comme d'autres bêta-2 agonistes, provoquant une bronchodilatation en relâchant les muscles lisses des voies aériennes, afin de traiter les exacerbations de l'asthme. Salmétérol est similaire dans l'action pour le formotérol, cependant formotérol a été démontré pour avoir une plus grande rapidité d'action que le salmétérol en raison d'une faible lipophilie, et a également été démontré que plus puissant - une dose de 12 mg de formotérol a été démontré pour être équivalent à une dose de 50 mg du salmétérol.
Fujimycin Absorption
En raison de la petite dose thérapeutique, les niveaux systémiques du salmétérol sont faibles ou indétectables après inhalation des doses recommandées.
Fujimycin Toxicite
Les symptômes de surdose comprennent l'angine (douleur thoracique), vertiges, bouche sèche, fatigue, syndrome pseudo-grippal, céphalées, une arythmie cardiaque, pression artérielle élevée ou basse, une glycémie élevée, insomnie, crampes musculaires, nausées, nervosité, accélération du rythme cardiaque, des convulsions et des tremblements. Par voie orale, aucun décès n'est survenu chez les rats à 1000 mg / kg (environ 81 000 fois la dose maximale recommandée chez l'inhalation quotidienne chez les adultes et environ 38 000 fois la dose maximale recommandée chez l'inhalation quotidienne de l'enfant en mg/m2).
Fujimycin Information pour les patients
PATIENT INFORMATION
Patients being treated with SEREVENT DISKUS should receive the following information and instructions. This information is
intended to aid them in the safe and effective use of this medication. It is not a disclosure of all possible adverse or
intended effects.
It is important that patients understand how to use the DISKUS appropriately and how to use SEREVENT DISKUS in relation to
other asthma or COPD medications they are taking. Patients should be given the following information:
1. The action of SEREVENT DISKUS may last up to 12 hours or longer. The recommended dosage (1 inhalation twice daily, morning
and evening) should not be exceeded.
2. Most patients are able to taste or feel a dose delivered from SEREVENT DISKUS. However, whether or not patients are able to
sense delivery of a dose, you should instruct them not to exceed the recommended dose of 1 inhalation twice daily, morning and
evening. You should instruct them to contact you or the pharmacist if they have questions.
3. SEREVENT DISKUS is not meant to relieve acute asthma or COPD symptoms and extra doses should not be used for that purpose.
Acute symptoms should be treated with an inhaled, short-acting bronchodilator (the physician should provide the patient with
such medication and instruct the patient in how it should be used).
4. Patients should not stop therapy with SEREVENT DISKUS for asthma or COPD without physician/provider guidance since symptoms
may worsen after discontinuation.
5. �When used for the treatment of EIB, 1 inhalation of SEREVENT DISKUS should be taken 30 minutes before exercise.
� Additional doses of SEREVENT should not be used for 12 hours.
� Patients who are receiving SEREVENT DISKUS twice daily should not use additional SEREVENT for prevention of EIB.
6. The physician should be notified immediately if any of the following situations occur, which may be a sign of seriously
worsening asthma or COPD:
� Decreasing effectiveness of inhaled, short-acting beta2-agonists
� Need for more inhalations than usual of inhaled, short-acting beta2-agonists
� Significant decrease in PEF or lung function as outlined by the physician
� Use of 4 or more inhalations per day of a short-acting beta2-agonist for 2 or more days consecutively
� Use of more than 1 canister (200 inhalations per canister) of an inhaled, short-acting beta2-agonist in an 8-week period.
7. SEREVENT DISKUS should not be used as a substitute for oral or inhaled corticosteroids. The dosage of these medications should
not be changed and they should not be stopped without consulting the physician, even if the patient feels better after initiating
treatment with SEREVENT DISKUS.
8. Patients should be cautioned regarding adverse effects associated with beta2-agonists, such as palpitations, chest pain, rapid
heart rate, tremor, or nervousness.
9. When patients are prescribed SEREVENT DISKUS, other medications for asthma and COPD should be used only as directed by the
physician.
10. SEREVENT DISKUS should not be used with a spacer device.
11. Patients who are pregnant or nursing should contact the physician about the use of SEREVENT DISKUS.
12. Effective and safe use of SEREVENT DISKUS includes an understanding of the way that it should be used:
� Never exhale into the DISKUS.
� Never attempt to take the DISKUS apart.
� Always activate and use the DISKUS in a level, horizontal position.
� Never wash the mouthpiece or any part of the DISKUS. KEEP IT DRY.
� Always keep the DISKUS in a dry place.
� Discard 6 weeks after removal from the moisture-protective foil overwrap pouch or after all blisters have been used (when the
dose indicator reads "0" ), whichever comes first.
13. For the proper use of SEREVENT DISKUS and to attain maximum benefit, the patient should read and follow carefully the Patient's
Instructions for Use accompanying the product.
Patients being treated with SEREVENT DISKUS should receive the following information and instructions. This information is
intended to aid them in the safe and effective use of this medication. It is not a disclosure of all possible adverse or
intended effects.
It is important that patients understand how to use the DISKUS appropriately and how to use SEREVENT DISKUS in relation to
other asthma or COPD medications they are taking. Patients should be given the following information:
1. The action of SEREVENT DISKUS may last up to 12 hours or longer. The recommended dosage (1 inhalation twice daily, morning
and evening) should not be exceeded.
2. Most patients are able to taste or feel a dose delivered from SEREVENT DISKUS. However, whether or not patients are able to
sense delivery of a dose, you should instruct them not to exceed the recommended dose of 1 inhalation twice daily, morning and
evening. You should instruct them to contact you or the pharmacist if they have questions.
3. SEREVENT DISKUS is not meant to relieve acute asthma or COPD symptoms and extra doses should not be used for that purpose.
Acute symptoms should be treated with an inhaled, short-acting bronchodilator (the physician should provide the patient with
such medication and instruct the patient in how it should be used).
4. Patients should not stop therapy with SEREVENT DISKUS for asthma or COPD without physician/provider guidance since symptoms
may worsen after discontinuation.
5. �When used for the treatment of EIB, 1 inhalation of SEREVENT DISKUS should be taken 30 minutes before exercise.
� Additional doses of SEREVENT should not be used for 12 hours.
� Patients who are receiving SEREVENT DISKUS twice daily should not use additional SEREVENT for prevention of EIB.
6. The physician should be notified immediately if any of the following situations occur, which may be a sign of seriously
worsening asthma or COPD:
� Decreasing effectiveness of inhaled, short-acting beta2-agonists
� Need for more inhalations than usual of inhaled, short-acting beta2-agonists
� Significant decrease in PEF or lung function as outlined by the physician
� Use of 4 or more inhalations per day of a short-acting beta2-agonist for 2 or more days consecutively
� Use of more than 1 canister (200 inhalations per canister) of an inhaled, short-acting beta2-agonist in an 8-week period.
7. SEREVENT DISKUS should not be used as a substitute for oral or inhaled corticosteroids. The dosage of these medications should
not be changed and they should not be stopped without consulting the physician, even if the patient feels better after initiating
treatment with SEREVENT DISKUS.
8. Patients should be cautioned regarding adverse effects associated with beta2-agonists, such as palpitations, chest pain, rapid
heart rate, tremor, or nervousness.
9. When patients are prescribed SEREVENT DISKUS, other medications for asthma and COPD should be used only as directed by the
physician.
10. SEREVENT DISKUS should not be used with a spacer device.
11. Patients who are pregnant or nursing should contact the physician about the use of SEREVENT DISKUS.
12. Effective and safe use of SEREVENT DISKUS includes an understanding of the way that it should be used:
� Never exhale into the DISKUS.
� Never attempt to take the DISKUS apart.
� Always activate and use the DISKUS in a level, horizontal position.
� Never wash the mouthpiece or any part of the DISKUS. KEEP IT DRY.
� Always keep the DISKUS in a dry place.
� Discard 6 weeks after removal from the moisture-protective foil overwrap pouch or after all blisters have been used (when the
dose indicator reads "0" ), whichever comes first.
13. For the proper use of SEREVENT DISKUS and to attain maximum benefit, the patient should read and follow carefully the Patient's
Instructions for Use accompanying the product.
Fujimycin Organismes affectes
Les humains et autres mammifères
